Key result
Higher serum levels of matrix metalloproteinase-2 (MMP-2) were strongly associated with increased all-cause mortality in patients with chronic systolic heart failure, whereas Galectin-3 showed only borderline significance.
Why the study?
Do serum markers of cardiac extracellular matrix turnover predict outcomes better than Galectin-3 in patients with chronic systolic heart failure?
Cohort (n=105)
No
Do serum markers of cardiac extracellular matrix turnover predict outcomes better than Galectin-3 in patients with chronic systolic heart failure?
Hazard Ratio: 554.336 (95% CI 16.8–17637.141)
p-value: p=<0.001
MMP-2 demonstrates stronger prognostic value for predicting mortality and heart failure admissions than Galectin-3 in patients with chronic systolic heart failure.
MMP-2 may support stronger mortality prediction than Gal-3 in chronic systolic HF; leaves open incremental value beyond standard markers.
BACKGROUND: Galectin-3 (Gal-3) shows the ability of survival prediction in heart failure (HF) patients. However, Gal-3 is strongly associated with serum markers of cardiac extracellular matrix (ECM) turnover. The aim of this study is to compare the impact of Gal-3 and serum markers of cardiac ECM turnover on prognostic prediction of chronic systolic HF patients. METHODS: Serum Gal-3, brain natriuretic peptide (BNP), extracellular matrix including type I and III aminoterminal propeptide of procollagen (PINP and PIIINP), matrix metalloproteinase-2, 9 (MMP-2, 9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) were analyzed. Cox regression analysis was used for survival analysis. RESULTS: A total of 105 (81 male) patients were enrolled. During 980±346 days follow-up, 17 patients died and 36 episodes of HF admission happened. Mortality of these patients was significantly associated with the log PIIINP (β= 15.380; P=0.042), log TIMP-1(β= 44.530; P=0.003), log MMP-2 (β= 554.336; P<0.001), log BNP (β= 28.273; P=0.034). Log Gal-3 (β= 7.484; P=0.066) is borderline associated with mortality. Mortality or first HF admission of these patients was significantly associated with the log TIMP-1(β= 16.496; P=0.006), log MMP-2 (β= 221.864; P<0.001), log BNP (β= 5.999; P=0.034). Log Gal-3 (β= 4.486; P=0.095) only showed borderline significance. In several models adjusting clinical parameters, log MMP-2 was significantly associated with clinical outcome. In contrast, log Gal-3 was not. CONCLUSION: The prognostic strength of MMP-2 to clinical outcome prediction in HF patients is stronger than Gal-3.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2014) conducted a cohort in Chronic systolic heart failure (n=105). Serum matrix metalloproteinase-2 (MMP-2) vs. Lower levels of MMP-2 was evaluated on All-cause mortality (HR 554.336, 95% CI 16.800-17637.141, p=<0.001). Higher serum levels of matrix metalloproteinase-2 (MMP-2) were strongly associated with increased all-cause mortality in patients with chronic systolic heart failure, whereas Galectin-3 showed only borderline significance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: